Sodium–glucose co‐transporter 2 (SGLT2) inhibitors, including dapagliflozin, canagliflozin, and empagliflozin, have proven benefits in reducing morbidity and mortality in heart failure, regardless of diabetes status [1, 2]. This evidence concerns the gene SLC5A2 and heart failure.